This raises a fascinating scenario that upon anti-CD47 treatment, DNA is released from tumor cells and taken up by DCs, resulting in the activation of STING and the production of type I IFN, which activates DCs for antigen cross-presentation (Fig. 1). Here, CD47 is linked to neoplasm.